MPP Teams Up With MedinCell For Investigational Malaria Transmission Treatment
Compound Does Not Protect Against Disease But Could Prevent Onward Transmission
The Medicines Patent Pool has secured a licensing deal with MedinCell for a long-acting injectable ivermectin drug formulation which could be used to prevent ongoing spread of malaria.
You may also be interested in...
Teva is starting Phase III trials for a long-acting injectable formulation of olanzapine, partner MedinCell has revealed. The move comes after the pair were knocked back on their partnered risperidone product earlier this year by the US FDA, with a new expected launch date for that product now also disclosed by the French company.
Generic abortion pill manufacturer GenBioPro has mounted a case in West Virginia alleging that its state-level ban of abortion is unconstitutional, as it is pre-empted by the US Food and Drug Administration’s federal opinion that mifepristone is a safe and legal medication.
IQVIA’s latest Global Use of Medicines report demonstrates the impact generics and biosimilars are set to have on global pharmaceutical spending, with losses of exclusivity expected to dampen spending growth over the next five years.